Winston & Strawn

Site Search

Professionals (396)
Capabilities (77)
Experience (128)
Insights & News (2,141)
Other Results (86)

Professionals 396 results

Sandra Edwards

Partner

San Francisco

+1 415-591-1412

vCard

Partner

San Francisco

Christopher Essig

Partner

Chicago

+1 312-558-6229

vCard

Partner

Chicago

Terry Dee

Partner

Chicago

+1 312-558-8112

vCard

Partner

Chicago

View All Professionals

Capabilities 77 results

Practice Area

Product Liability & Mass Torts

Major multinational companies trust Winston to defend their products and reputations in high-profile, high-stakes product liability and mass tort claims. Our Product Liability & Mass Torts Practice is one of the industry’s most seasoned, with a deep bench of experienced lawyers and a unique combination of extensive trial experience and expansive technical knowledge....Read more

Practice Area

Derivatives & Structured Products

Winston represents swap dealers, major swap participants, financial intermediaries, hedge funds, national exchanges, and end-users in a broad array of derivative transactions ranging from highly structured transactions to more traditional trading or hedging transactions, and in regulatory and enforcement issues related to commodities and derivatives....Read more

Industry

Medical Devices

The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic fluctuations. To pave the way for a more accessible and innovative health care landscape—including advances in wearables, implants, diagnostics, mobility, drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable depth and breadth of our sector-focused and skilled attorneys in the U.S. and abroad. Our Health Care & Life Sciences Industry Group engages clients at all points in the product development life cycle to provide sound advice and practical solutions regardless of the client’s size or the complexity of their need. We help clients navigate today’s complex regulatory landscape, defend products and reputations in the face of high-profile product liability and mass tort claims, protect innovative intellectual property (IP), and leverage cross-border experience to advise on commercial transactions....Read more

Experience 128 results

Experience

August 19, 2025

Winston Advised Ellipsis Onshore Holdings in the Acquisition of Oil and Gas Non-Operated Assets in the Permian Basin of Texas and New Mexico

Winston advised Ellipsis U.S. Onshore Holdings LLC, a portfolio company of the Westlawn Group, in connection with the acquisition of high-quality, non-operated working interests in the Permian Basin of Texas and New Mexico—adding approximately 4,000 barrels of oil equivalent per day in net production and over 600 gross remaining drilling locations. This strategic transaction strengthens Ellipsis’ Delaware Basin footprint and supports its strategy of scaling through high-margin, low-cost assets....Read more

Experience

May 27, 2025

PicoCELA Inc. Closes $1.8 Public Offering

Winston & Strawn represented Revere Securities LLC acted as the lead placement agent in connection with PicoCELA, Inc. in the closing of its public offering of 6,100,000 American Depositary Shares ("ADSs") at a public placement price of $0.30 per ADS. PicoCELA, Inc. received an aggregate gross proceeds of $1.83 million before deducting placement agent commission and other offering expenses. Each ADS represents one common share of the Company....Read more

Experience

April 11, 2025

Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering

Winston & Strawn is serving as underwriters counsel to R.F. Lafferty in connection with Cuprina Holdings, a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds as well as cosmeceuticals for the health and beauty sector, in its announced closing of $12,000,000 initial public offering. The Offering consists of 3,000,000 ordinary shares at a public offering price of $4 per share, for total gross proceeds of $12,000,000, before deducting underwriting discounts and offering expenses....Read more

View All Experience

Insights & News 2,141 results

Global Trade & Foreign Policy Insights

September 26, 2025

3 Min Read

USMCA at a Crossroads: Stakeholders Invited to Shape the Future

The Office of the United States Trade Representative (USTR) has initiated a public consultation process in preparation for the upcoming joint review of the United States–Mexico–Canada Agreement (USMCA), scheduled for July 1, 2026. This process is mandated by Article 34.7 of the USMCA and section 611 of the USMCA Implementation Act, which require a comprehensive evaluation of the agreement’s operation and a determination by each party on whether to extend the agreement for an additional 16-year term.

Direct Sellers Update: Regulation, Law & Policy

September 23, 2025

2 Min Read

Direct Seller Defeats Class Certification in Misclassification Case

As we’ve written previously, direct selling companies are facing a wave of lawsuits, primarily in California, claiming that distributors do not qualify as independent contractors and instead are misclassified employees. Just recently, however, a California court refused to certify a class on these claims—an important outcome for all direct sellers.

Tax Impacts

September 19, 2025

5 Min Read

House Ways & Means Committee Advances Two Tax Procedure Bills to Revise Penalty Approval and Tax Court Powers

On September 17, 2025, the House Committee on Ways and Means advanced two bipartisan tax-procedure measures. Both bills propose technical reforms aimed at reducing procedural friction in federal tax administration and litigation.

View All Insights & News

Other Results 86 results

Law Glossary

What Are Interchangeable Biological Products?

A biological product is interchangeable if it is biosimilar to the reference product and is expected to produce the same clinical result as the reference product in any given patient. A biosimilar product that is deemed to be interchangeable by the FDA means the biosimilar product can be substituted for the reference product by a pharmacist without consulting the prescriber. The specific requirements for substitution vary by state....Read more

Site Content

What Is General Causation?

In the product liability context, general causation is the legal and scientific determination of whether the product in question has the inherent capability to cause the alleged injury under certain circumstances. Establishment of general causation is a critical aspect of a plaintiff’s case, and typically requires scientific evidence, such as epidemiology or toxicology, and expert testimony to establish a causal connection between the product’s design, manufacturing, or warnings and the injury or injuries at issue. As contrasted to specific causation, the focus in a general causation inquiry is on whether the product or exposure, as a general matter, can cause the type of injury claimed by the plaintiff. A general causation inquiry does not assess any facts unique to a particular plaintiff....Read more

Site Content

What Is a Manufacturing Defect?

In the product liability context, a manufacturing defect claim arises when a plaintiff alleges that a mistake occurred during the manufacturing process of a particular product that made it different from its intended design. Unlike a design defect claim, which concerns the inherent dangers of a product’s design, manufacturing defect claims focus on deviations from the product’s intended specifications....Read more